CRIMSON
CRIMSON: A multicentre randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Diabetic Retinopathy
Study Purpose
The purpose of this study, called CRIMSON, is to evaluate different dosing frequencies of an experimental study drug called BI 764524 in participants with NPDR. The study also evaluates if BI 764524 is safe and effective in treating your NPDR, compared with a dummy (sham) treatment or Eylea® (aflibercept), a comparator drug. A comparator drug is compared with an experimental study drug. A comparator is often the current standard treatment for the disease in question.
Who Can Participate
Age: 18 years and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00002282
- StudyID: 2024-01475
- ClinicalTrials.gov: NCT06321302
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422